US OptionsDetailed Quotes
SAGE250117C30000
- 0.05
- 0.000.00%
15min DelayClose Dec 24 13:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume68 Open Interest30.00Strike Price0.00Turnover310.98%IV448.36%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0376Delta0.0191Gamma109.60Leverage Ratio-0.0073Theta0.0001Rho4.12Eff Leverage0.0011Vega
Sage Therapeutics Stock Discussion
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
oooooo
Gapping up
$Salesforce (CRM.US)$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group (UBS.US)$ popp...
No comment yet